RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Larimar Therapeutics P/E 2024

Larimar Therapeutics P/E

-3.52

Larimar Therapeutics Dividend yield

Ticker

LRMR

ISIN

US5171251003

WKN

A2P5PP

As of Apr 27, 2024, Larimar Therapeutics's P/E ratio was -3.52, a -22.47% change from the -4.54 P/E ratio recorded in the previous year.

The Larimar Therapeutics P/E history

Larimar Therapeutics Aktienanalyse

What does Larimar Therapeutics do?

Larimar Therapeutics Inc is a US biotechnology company focused on developing therapies for rare genetic diseases. It was founded in 2018 and is based in Philadelphia, Pennsylvania. The company's mission is to accelerate the development of therapies for patients with rare genetic diseases through collaboration with academic researchers, patient organizations, and industry partners. They are active in various therapeutic areas, including neurological diseases, genetic metabolic disorders, and rare inherited diseases, with a diverse portfolio of drug candidates in different stages of clinical development. Their main focus is on developing therapies for Friedreich's ataxia, a rare neurological disease, and other neurologic disorders. They are also working on therapies for rare genetic metabolic disorders such as PKU and HFI. Larimar Therapeutics aims to improve the quality of life for patients with rare inherited diseases and adopts an innovative and patient-centered approach to their drug development. Collaborations and partnerships are integral to their strategy in order to make faster progress in the treatment of these often severe diseases. Larimar Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Larimar Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Larimar Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Larimar Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Larimar Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Larimar Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Larimar Therapeutics Stock

What is the price-to-earnings ratio of Larimar Therapeutics?

The price-earnings ratio of Larimar Therapeutics is currently -3.52.

How has the price-earnings ratio of Larimar Therapeutics changed compared to last year?

The price-to-earnings ratio of Larimar Therapeutics has increased by -22.47% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Larimar Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Larimar Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Larimar Therapeutics affect the company?

An increase in the price-earnings ratio of Larimar Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Larimar Therapeutics affect the company?

A decrease in the price-earnings ratio of Larimar Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Larimar Therapeutics?

Some factors that influence the price-earnings ratio of Larimar Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Larimar Therapeutics pay?

Over the past 12 months, Larimar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Larimar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Larimar Therapeutics?

The current dividend yield of Larimar Therapeutics is .

When does Larimar Therapeutics pay dividends?

Larimar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Larimar Therapeutics?

Larimar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Larimar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Larimar Therapeutics located?

Larimar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Larimar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Larimar Therapeutics from 4/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/27/2024.

When did Larimar Therapeutics pay the last dividend?

The last dividend was paid out on 4/27/2024.

What was the dividend of Larimar Therapeutics in the year 2023?

In the year 2023, Larimar Therapeutics distributed 0 USD as dividends.

In which currency does Larimar Therapeutics pay out the dividend?

The dividends of Larimar Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Larimar Therapeutics

Our stock analysis for Larimar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Larimar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.